Table 1. Baseline characteristics of the patients.
| Total (n=178) | ||
|---|---|---|
| Age, year, median (IQR) | 69.27 (63.78-79.44) | |
| Gender, no. (%) | ||
| Female | 30 (16.9) | |
| Male | 148 (83.1) | |
| BMI, median (IQR) | 27.29 (24.2-29.4) | |
| Hypertension, no. (%) | 108 (60.7) | |
| Diabetes, no. (%) | 54 (30.3) | |
| Dyslipidemia, no. (%) | 36 (20.2) | |
| NLR, median (IQR) | 2.41 (1.69-3.62) | |
| Pathologic stage, no. (%) | ||
| pTa | 138 (77.5) | |
| pT1 | 40 (22.5) | |
| Pathologic grade, no. (%) | ||
| Low grade | 126 (70.3) | |
| High grade | 40 (22.5) | |
| Concomitant CIS. no. (%) | ||
| No | 128 (71.9) | |
| Yes | 50 (28.1) | |
| No. of tumours (%) | ||
| 1 | 118 (66.3) | |
| 2-7 | 54 (30.3) | |
| ≥ 8 | 6 (3.4) | |
| Tumour size, cm, no. (%) | ||
| < 3cm | 96 (53.9) | |
| ≥ 3cm | 82 (46.1) | |
| Smoking status | ||
| Never | 18 (10.1) | |
| Former | 74 (41.6) | |
| Current | 86 (48.3) | |
| EORTC Recurrence | ||
| Low | 48 (27.0) | |
| Intermediate | 126 (70.3) | |
| High | 4 (2.2) | |
| EORTC Progression | ||
| Low | 58 (32.6) | |
| Intermediate | 82 (46.1) | |
| High | 38 (21.3) | |
IQR = interquartile range; BMI = body mass index; NLR = neutrofil-to-lymphocyte ratio; CIS = carcinoma in situ